ORIC Pharmaceuticals announces agreement with Cancer Research UK to advance CIP2A-targeted therapy into clinical development

ORIC Pharmaceuticals announced an agreement with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical development.

Detected & updated continuously · Source: Nebula